Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 176 - 200 of 14739 in total

Axitinib

Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation...
Approved
Investigational
Matched Description: … [L6676] Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. ... [A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations. …
Matched Categories: … Benzamides and benzamide derivatives ... Antineoplastic and Immunomodulating Agents ... UGT1A1 Substrates with a Narrow Therapeutic Index ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index …

Ceftriaxone

Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges , eyes , and inner ear . Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S.aureus. Ceftriaxone...
Approved
Matched Description: … meninges[A215582], eyes[A215647], and inner ear[A215627]. ... [A215582] It has a very long half-life compared to other cephalosporins and is high penetrable into the ... Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins …
Matched Mixtures name: … Hovid Ceftriaxone 1g with Lidocaine 1% ... Hovid-Ceftriaxone 0.5g with Lidocaine 1% …
Matched Products: … Ceftriaxone and Dextrose …

Copanlisib

Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies. Copanlisib was granted accelerated...
Approved
Investigational
Matched Description: … Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity ... against the alpha and delta isoforms. ... , that exists in different isoforms and is often overexpressed in hematological malignancies. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index …

Darunavir

Darunavir is a protease inhibitor used with other HIV protease inhibitor drugs as well as ritonavir for the effective management of HIV-1 infection. As a second-generation protease inhibitor, darunavir is designed to combat resistance to standard HIV therapy.[A2278,A2281] It was initially approved by the FDA in 2006. Darunavir is being...
Approved
Matched Description: … Darunavir is a protease inhibitor used with other HIV protease inhibitor drugs as well as [ritonavir] ... [A191682] Clinical trials are underway and are expected to conclude in August 2020.[L12066] …
Matched Categories: … darunavir and ritonavir ... darunavir and cobicistat ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics ... emtricitabine, tenofovir alafenamide, darunavir and cobicistat …
Matched Products: … Darunavir 600 and 800 mg …

Procainamide

A derivative of procaine with less CNS action.
Approved
Matched Description: … A derivative of procaine with less CNS action. …
Matched Categories: … Benzamides and benzamide derivatives ... OCT2 Substrates with a Narrow Therapeutic Index ... MATE 1 Substrates with a Narrow Therapeutic Index ... MATE 2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index …

Dioxybenzone

Dioxybenzone, or benzophenone-8, is an organic compound derived from DB01878 that is used as a sunscreen agent. It absorbed UV-B and UV-AII rays. Dioxybenzone is an approved sunscreen ingredient in concentrations up to 3% .
Approved
Matched Description: … It absorbed UV-B and UV-AII rays. …
Matched Mixtures name: … Hydroquinone with sunscreens ... Perrigo Hydroquinone with sunscreens ... Perrigo Hydroquinone with sunscreens …

Ixabepilone

Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is...
Approved
Investigational
Matched Description: … Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Cytotoxic Antibiotics and Related Substances ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Niraparib

Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or...
Approved
Investigational
Matched Description: … [L43277] Niraparib is selective towards PARP-1 and PARP-2. ... [L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health …
Matched Categories: … niraparib and abiraterone ... Antineoplastic and Immunomodulating Agents ... MATE 1 Substrates with a Narrow Therapeutic Index ... MATE 2 Substrates with a Narrow Therapeutic Index ... P-glycoprotein substrates with a Narrow Therapeutic Index …

Curcumin

Curcumin, also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and in Curcuma xanthorrhiza oil. It is a highly pleiotropic molecule that exhibits antibacterial, anti-inflammatory, hypoglycemic, antioxidant, wound-healing, and antimicrobial activities . Due to these properties, curcumin has been investigated for the treatment and...
Approved
Investigational
Matched Description: … in [Curcuma xanthorrhiza oil]. ... also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and ... molecule that exhibits antibacterial, anti-inflammatory, hypoglycemic, antioxidant, wound-healing, and …

Tetracycline

Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the...
Approved
Vet approved
Withdrawn
Matched Description: … exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and ... It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane …
Matched Mixtures name: … Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride ... Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Hydrochloride …
Matched Categories: … Alimentary Tract and Metabolism ... tetracycline and oleandomycin ... Ophthalmological and Otological Preparations ... lansoprazole, tetracycline and metronidazole ... Antiinfectives and Antiseptics for Local Oral Treatment …
Matched Products: … MeaStem First Aid and Antibiotic …

Erlotinib

Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)...
Approved
Investigational
Matched Description: … polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential ... potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with ... EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index …

Valproic acid

Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into...
Approved
Investigational
Matched Description: … Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in ... [A178051] It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for ... It is currently a compound of interest in the field of oncology for its anti-proliferative effects and …
Matched Categories: … UGT1A1 Substrates with a Narrow Therapeutic Index ... UGT1A3 Substrates with a Narrow Therapeutic Index ... UGT1A6 Substrates with a Narrow Therapeutic Index ... UGT1A9 Substrates with a Narrow Therapeutic Index ... UGT2B7 Substrates with a Narrow Therapeutic Index …

Simethicone

Simethicone is a silicon based surfactant that decreases the surface tension of gastrointestinal gas bubbles to facilitate their elimination. It has a favourable safety profile as it is not systemically absorbed. Simethicone has been in use since the 1940s but was granted FDA approval in 1952.
Approved
Matched Mixtures name: … Gelusil Antacid and Anti-gas ... Antacid Regular With Anti-gas ... Tums Chewy Bites with Gas Relief …

Haloperidol

Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularly within...
Approved
Matched Description: … [F4645] It is also used off-label for the management of chorea associated with Huntington's disease and ... However, these findings contradict the findings from studies in vitro with human liver microsomes and ... [A32346] First-generation antipsychotic drugs have largely been replaced with second- and third-generation …

Oxygen

Oxygen is an element displayed by the symbol O, and atomic number 8. It is an essential element for human survival. Decreased oxygen levels may be treated with medical oxygen therapy. Treatment with oxygen serves to increase blood oxygen levels and also exerts a secondary effect of decreasing blood flow...
Approved
Vet approved
Matched Description: … Treatment with oxygen serves to increase blood oxygen levels and also exerts a secondary effect of decreasing ... Decreased oxygen levels may be treated with medical oxygen therapy. ... Oxygen is an element displayed by the symbol O, and atomic number 8. …
Matched Mixtures name: … Carbon Dioxide and Oxygen Mixture, Compressed, Oxidizing, N.O.S. …
Matched Products: … OSSIGENO FARMA GAS MEDICAL AND TECHNICAL GASES …

Magaldrate

Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.
Approved
Withdrawn
Matched Description: … Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and …
Matched Categories: … Antacids With Antiflatulents ... Alimentary Tract and Metabolism ... magaldrate and antiflatulents ... Aluminum and magnesium containing antacids …

Amitriptyline

Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties.
Approved
Matched Mixtures name: … Perphenazine and Amitriptyline Hydrochloride ... Perphenazine and Amitriptyline Hydrochloride ... Chlordiazepoxide and Amitriptyline HCl …
Matched Categories: … amitriptyline and psycholeptics ... Tricyclics and Other Norepinephrine-reuptake Inhibitors ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index …

Clofarabine

Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic...
Approved
Investigational
Matched Description: … It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. ... Its potential use in acute myeloid leukaemia (AML) and juvenile myelomonocytic leukaemia (JMML) has been …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides ... OCT2 Substrates with a Narrow Therapeutic Index ... OAT3/SLC22A8 Substrates with a Narrow Therapeutic Index …

Sodium acetate

Sodium Acetate is chemically designated CH3COONa, a hygroscopic powder very soluble in water. Sodium acetate could be used as additives in food, industry, concrete manufacture, heating pads and in buffer solutions. Medically, sodium acetate is important component as an electrolyte replenisher when given intravenously. It is mainly indicated to correct...
Approved
Investigational
Matched Description: … It can be used also in metabolic acidosis and for urine alkalinization. ... Sodium acetate could be used as additives in food, industry, concrete manufacture, heating pads and in …
Matched Mixtures name: … Plasma-Lyte 148 and dextrose ... Normosol-R and Dextrose ... Plasma-Lyte M and Dextrose …
Matched Categories: … Blood and Blood Forming Organs ... Blood Substitutes and Perfusion Solutions …

Baricitinib

Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was...
Approved
Investigational
Matched Description: … [A248405] While baricitinib was granted emergency use as a treatment for COVID-19 in combination with ... By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune ... European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... MATE 2 Substrates with a Narrow Therapeutic Index ... OAT3/SLC22A8 Substrates with a Narrow Therapeutic Index ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Dacomitinib

Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on...
Approved
Investigational
Matched Description: … [A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Dasatinib

Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein...
Approved
Investigational
Matched Description: … BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the ... ) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region ... pathogenesis of CML and 15-30% of ALL cases. …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index …

Bendamustine

Bendamustine is a nitrogen mustard drug which has been used in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL). Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine...
Approved
Investigational
Matched Description: … a nitrogen mustard drug which has been used in the treatment of chronic lymphocytic leukemia (CLL) and ... Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks ... It is active against both active and quiescent cells, although the exact mechanism of action is unknown …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index …

Doxorubicin

Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed...
Approved
Investigational
Matched Description: … terminates with a primary alcohol group compared to the methyl group of daunorubicin. ... cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with ... L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which excludes patients with …
Matched Categories: … Anthracyclines and Related Substances ... Antineoplastic and Immunomodulating Agents ... Cytotoxic Antibiotics and Related Substances ... BSEP/ABCB11 Substrates with a Narrow Therapeutic Index ... P-glycoprotein substrates with a Narrow Therapeutic Index …

Flurbiprofen

Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis....
Approved
Investigational
Matched Description: … Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic ... and analgesic activity. ... Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen. …
Matched Categories: … Antiinflammatory and Antirheumatic Products ... Topical Products for Joint and Muscular Pain ... Antiinflammatory and Antirheumatic Products, Non-Steroids …
Matched Products: … Strepsils MaxPro Honey and Lemon lozenges 8.75mg …
Displaying drugs 176 - 200 of 14739 in total